Leerink Partners raised its price target on Heron Therapeutics (NASDAQ: HRTX) to $46.00 (from $36.00) while maintaining a Outperform rating.

Analyst PT Change

Heron Therapeutics (HRTX) Prices $200M Common Share OfferingJune 26, 2018 5:39 AM Heron Therapeutics (HRTX) PT Raised to $80 at Evercore ISIJune 22, 2018 8:33 AM Heron Therapeutics (HRTX) PT Raised to $44 at BofA/Merrill LynchJune 22, 2018 6:31 AM Heron Therapeutics (HRTX) PT Raised to $50 at OppenheimerJune 22, 2018 1:41 AM Heron Therapeutics (HRTX) PT Raised to $41 at Mizuho SecuritiesJune 22, 2018 1:38 AM Heron Therapeutics (HRTX) PT Raised to $66 at Needham & CompanyJune 21, 2018 3:48 PM Heron Therapeutics (HRTX) PT Raised to $54 at Cowen; Sees HTX-011 as $1B+ OpportunityJune 21, 2018 1:15 PM Heron Therapeutics (HRTX) PT Raised to $51 at JefferiesJune 21, 2018 11:39 AM Heron Therapeutics (HRTX) PT Raised to 'Street High' $80 at Evercore ISIJune 21, 2018 10:23 AM